Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2024-200458

Published: 2024

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Nicolaus Kröger, Matthias Eder, Gerard Socie, Didier Blaise, Thomas Schroeder, Hélène Labussière-Wallet, Johan Maertens, Alessandro Busca, Edouard Forcade, Tobias Gedde-Dahl, Alessandro Rambaldi, Claude-Éric Bulabois, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 505.

https://doi.org/10.1182/blood-2024-194057

Published: 2024

Journal Articles

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2024) 144 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2024-203964

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Patricia Lopez Pereira, Ali Bazarbachi, Ambroise Marçais, Maud Ngoya, Irma Khvedelidze, Ben Carpenter, Victoria Potter, Flore Sicre de Fontbrune, Alina Daniela Tanase, Lucy Cook, Francesca Kinsella, Emma Nicholson, Annoek E. C. Broers, Jennifer Clay, Sr., Hélène Labussière-Wallet, Fabio Ciceri, Bertram Glass, Olivier Hermine, Ana Maria Sureda Balari

Blood (2024) 144 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2024-207307

Published: 2024

Journal Articles

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Blood (2024) 144 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2024-204824

Published: 2024

Journal Articles

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Blood (2024) 143 (24): 2534–2543.

https://doi.org/10.1182/blood.2023023697

Published: 2024

Includes: Supplemental data

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Patrice Chevallier, Anne Thiebaut, Sylvie François, Sylvain Chantepie, Marie Thérèse Rubio, Hélène Labussière-Wallet, Eolia Brissot, Natacha Maillard, Anne Huynh, Valerie Coiteux, Alice Garnier, Amandine Le Bourgeois, Pierre Peterlin, Thierry Guillaume

Blood (2023) 142 (Supplement 1): 4957.

https://doi.org/10.1182/blood-2023-179734

Published: 2023

Journal Articles

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2023-180686

Published: 2023

Journal Articles

Resolution of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Defibrotide Following HCT in Adult and Pediatric Patients: Pooled Analysis of Defifrance and EBMT PASS Registries

Mohamad Mohty, Franco Locatelli, Didier Blaise, Regis Peffault De Latour, Hélène Labussière-Wallet, Vian Amber, Virginie Gandemer, Deborah Gutierrez, Nalina Dronamraju, Jean-Hugues Dalle, Micha Srour

Blood (2023) 142 (Supplement 1): 3527.

https://doi.org/10.1182/blood-2023-185963

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Blood (2023) 142 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2023-179829

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Blood (2023) 142 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2023-180581

Published: 2023

Journal Articles

UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis

Blood (2023) 142 (Supplement 1): 4977.

https://doi.org/10.1182/blood-2023-173727

Published: 2023

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schröder, Rudolf Trenschel, Miroslaw Markiewicz, Hélène Labussière-Wallet, Péter Reményi, Fabio Ciceri, Friedrich Stölzel

Blood (2023) 142 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2023-180816

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2023-184995

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr -Mutated Myelofibrosis

Blood (2022) 140 (Supplement 1): 10608–10610.

https://doi.org/10.1182/blood-2022-163048

Published: 2022

Journal Articles

Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis

Blood (2022) 140 (Supplement 1): 4876–4877.

https://doi.org/10.1182/blood-2022-165606

Published: 2022

NARROW

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Resolution of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Defibrotide Following HCT in Adult and Pediatric Patients: Pooled Analysis of Defifrance and EBMT PASS Registries

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr -Mutated Myelofibrosis

Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only